dr. kahl discusses polatuzumab vedotin in lymphoma
Published 6 years ago • 403 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
43:40
polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma.
-
1:49
dr. kahl discusses the construction of adcs for lymphoma treatment
-
1:32
dr. kahl on findings from the l-mind study with tafasitamab in dlbcl
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
1:25
dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
-
2:22
dr. herrera discusses polatuzumab vedotin in dlbcl
-
4:25
phase ib polatuzumab vedotin trial
-
1:35
dr. pagel on the implications of polatuzumab vedotin approval in dlbcl
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
2:07
dr. hou on polatuzumab vedotin in dlbcl
-
4:59
a breakthrough therapy: polatuzumab vedotin plus br for r/r dlbcl
-
2:00
polatuzumab vedotin and car t-cell therapy for diffuse large b-cell lymphoma
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
1:15
polatuzumab vedotin combined with chemotherapy in untreated large b-cell lymphoma
-
3:25
how will front-line use of polatuzumab vedotin influence patient outcomes in dlbcl?
-
4:56
catherine diefenbach: polatuzumab vedotin for follicular lymphoma
-
4:39
treatment alternatives to chemotherapy in r/r dlbcl
-
5:33
management of refractory follicular lymphoma